PTO/SB/08A (10-01) Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE on Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

First Named Inventor Art Unit Examiner Name

Application Number

10/088,952 March 22, 2002 Leppla, Stephen Not yet assigned

2002

Not yet assigned Sheet of Attorney Docket Number 015280-405100US

Filing Date

1600/2900

			U.S. PATENT D	OCUMENTS	
		Document Number			
Examiner	Cite No.1	Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant <u>Figu</u> res Appear
3/5	AA	US-5,677,274	10/14/97	Leppla et al.	
BF	AB	US-5,817,771	10/06/98	Hagen et al.	
	AC	US-			
	AD	US-			
	AE	US-			
	AF	US-			
	AG	US-			
	AH	US-			
	Al	US-			
	AJ	US-			
	AK	US-			
	AL	US-	_		
	AM	US-			
	AN	US-			***
	AO	US-			
	AP	US-			
	AQ	US-			
	AR	US-			
	AS	US-			
	AT	US-			

	FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Foreign Patent Document				Pages, Columns, Lines,	T	
		Country Code ³	Number ⁴	Kind Code ^s (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T⁵
	AU							
	AV							
	AW	1						
	AX					· · · · · · · · · · · · · · · · · · ·	· · · · · · · · · · · · · · · · · · ·	
	AY							H
	AZ							H
	BA							H
	BB							H

Examiner Signature	Sienlan Fetterat	Date Considered	12/2/04

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer. US Patent and Trademark Office. Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

SF 1416157 v1

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional) 2 Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Stind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

he Paperwork R Substitute for form

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE on Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known **Application Number** 10/088,952 March 22, 2002 Filing Date RECEIVED First Named Inventor Leppla, Stephen Art Unit Not yet assigned DEC \$ 1 2002 Not yet assigned

(use as many sheets as necessary)

Examiner Name 015280-405100US Attorney Docket Number of 2 Sheet

TECH CENTER 1600/2900

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue				
TX.	вс	LIAW, L and CRAWFORD, H.C., "Functions of the extracellular matrix and matrix degrading proteases during tumor progression" Braz. J. of Med. and Biol. Res. (1999) 32:805-812	z. J. of Med. and Biol. Res. (1999) 32:805-812		
MAZAR, A.P. and JONES, T.R., Abstract, XP-002131000, #146 "High-affinity, small cyclic peptide urokinase plasminogen activator receptor (uPAR)-targeting ligands localize reporter and therapeutic conjugates to the surfa of tumor cells and stimulated endothelial cells," Angst. Phar.					
	BE				
, 112	BF				
	BG				
	вн				
	Ві				
	ВЈ				
	вк				
	BL				
	ВМ				

Examiner Signature Signature	Date Considered 12 2 CH
------------------------------	-------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

SF 1416157 v1

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached